98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

洛索洛芬

白色至淡黄色结晶粉末

DMSO : 46 mg/mL (186.8 mM)

Ethanol : 46 mg/mL (186.8 mM)

Loxoprofen sodium(LOX) does not affect the proliferation and viability of LLC cells in vitro. HUVECs treated with LOX results in the inhibition of the tubular formation. Treatment with 50 mg/ml LOX reveals a 33% decline in in vitro angiogenesis, compared with vehicle-treated HUVECs. This inhibition is presumably due to inhibition of VEGF activity.

Loxoprofen sodium (LOX), inhibits in vivo growth of implanted Lewis lung carcinoma (LLC). Intratumoral vessel density in LOX-treated mice is significantly lower than that of mice without treatment. Intratumoral expressions of vascular endothelial growth factor (VEGF) mRNA are attenuated by the LOX treatment. LOX suppresses both intratumoral and systemic VEGF protein in LLC-implanted mice. LOX alsoinhibits tubular formation of primary cultured human umbilical vein endothelial cells, presumably due to the inhibition of VEGF. In patients with advanced non-small cell lung cancer, LOX medication (120 mg/day) for a week significantly decreases the plasma VEGF level.